AnaptysBio, Inc. (ANAB)

AnaptysBio, Inc. (ANAB) Healthcare & Pipeline Overview

AnaptysBio, Inc. is a clinical-stage biotechnology company developing innovative therapeutic antibodies for inflammation and immuno-oncology, including Imsidolimab, Rosnilimab, and ANB032. Leveraging strategic collaborations with industry leaders, the company focuses on advancing its pipeline to address significant unmet medical needs in dermatological and immune-mediated conditions.

What Is the Investment Thesis for ANAB?

AnaptysBio, Inc. operates as a clinical-stage biotechnology company with a pipeline focused on inflammation and immuno-oncology, representing significant market opportunities. The company's current market capitalization stands at $1.86 billion, reflecting investor sentiment towards its future potential rather than current profitability, as evidenced by a negative profit margin of -11.5%. Despite this, a robust gross margin of 116.4% suggests strong pricing power or efficient cost management related to its intellectual property and licensing activities. The company's positive free cash flow of $0.01 billion indicates some operational efficiency in managing its R&D expenditures. Key value drivers include the advancement of its lead product candidates—Imsidolimab, Rosnilimab, and ANB032—through clinical trials. Positive clinical data readouts and subsequent regulatory milestones for these programs would serve as significant growth catalysts. Strategic collaborations with GlaxoSmithKline and Bristol-Myers Squibb also provide external validation, potential funding, and pathways for commercialization, reducing some of the inherent risks associated with a clinical-stage biotech. The company's low Beta of 0.41 suggests relatively lower volatility compared to the broader market, which could appeal to certain investor profiles. However, as a clinical-stage entity, the investment carries inherent risks related to trial success, regulatory approvals, and the competitive landscape, which are critical considerations for potential returns.

Based on FMP financials and quantitative analysis

ANAB Key Highlights

• Market Capitalization of $2.75B, reflecting significant investor interest in its clinical-stage pipeline.
• Negative Profit Margin of -11.5%, typical for a biotechnology company heavily investing in research and development prior to commercialization.
• Exceptional Gross Margin of 116.4%, indicating strong intellectual property value and potential for high profitability upon successful commercialization or licensing.
• Positive Free Cash Flow of $0.01 billion, demonstrating some operational cash generation despite being a clinical-stage company.
• Low Beta of 0.41, suggesting lower stock price volatility relative to the overall market, potentially appealing to risk-averse investors within the biotech sector.

Who Are ANAB's Competitors?

ANAB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ANAB's Key Strengths?

• Diverse clinical-stage pipeline targeting significant inflammatory and immuno-oncology indications.
• Strategic collaboration and license agreements with major pharmaceutical companies like GSK and BMS.
• Proprietary antibody discovery platform capable of generating novel therapeutic candidates.
• Specific product candidates like Imsidolimab, Rosnilimab, and ANB032 with distinct mechanisms of action.

What Are ANAB's Weaknesses?

• Clinical-stage company with no commercialized products, leading to negative profit margins.
• High reliance on successful outcomes of clinical trials and regulatory approvals.
• Significant capital requirements for ongoing research and development.
• Valuation heavily dependent on future pipeline success, which carries inherent uncertainty.

What Could Drive ANAB Stock Higher?

• Clinical Trial Data Readouts: Anticipated announcements of clinical trial results for Imsidolimab, Rosnilimab, or ANB032, which could significantly impact the company's valuation and future prospects.
• Regulatory Milestones: Potential progression of product candidates to later stages of regulatory review or submission of marketing applications in key jurisdictions.
• Advancement of Partnered Programs: Continued progress of antibody programs under collaboration agreements with GlaxoSmithKline and Bristol-Myers Squibb, potentially triggering milestone payments and validating the company's platform.
• Initiation of New Clinical Trials: Commencement of new clinical studies for existing pipeline candidates in additional indications or for novel antibody programs.

What Are the Key Risks for ANAB?

• Clinical Trial Failures: The inherent risk that any of AnaptysBio's clinical-stage product candidates may fail to demonstrate sufficient efficacy or safety in ongoing or future clinical trials.
• Regulatory Approval Challenges: The possibility of delays or outright rejection of marketing applications by regulatory authorities (e.g., FDA, EMA) for its drug candidates.
• Intense Competition: The biotechnology industry is highly competitive, with numerous companies developing therapies for inflammation and immuno-oncology, potentially impacting market share and pricing.
• Dependence on Collaborations: Reliance on the success and continued commitment of strategic partners like GlaxoSmithKline and Bristol-Myers Squibb for the development and potential commercialization of certain programs.
• Funding and Liquidity: As a clinical-stage company with negative profit margins, AnaptysBio may require additional capital to fund its extensive research and development activities, which could lead to dilution for existing shareholders.

What Are the Growth Opportunities for ANAB?

• **Advancement of Imsidolimab in Dermatological Inflammatory Diseases**: Imsidolimab, an IL-36R inhibitor, targets a range of dermatological inflammatory diseases. The global market for dermatological therapeutics is substantial, estimated to be tens of billions of dollars and growing. Successful progression through late-stage clinical trials and eventual regulatory approval for specific indications could unlock significant revenue streams. The unique mechanism of action could differentiate it in crowded markets, offering a novel treatment option for patients who do not respond to existing therapies. This opportunity has a multi-year timeline, contingent on clinical trial outcomes and regulatory review processes.
• **Development of Rosnilimab for T-cell Driven Inflammatory Diseases**: Rosnilimab, an anti-PD-1 agonist antibody, represents a novel approach to modulating T-cell activity to suppress inflammatory diseases. The market for T-cell mediated inflammatory conditions, such as certain autoimmune disorders, is vast and underserved by highly effective, well-tolerated treatments. Demonstrating efficacy and safety in clinical trials could position Rosnilimab as a significant therapeutic option, potentially capturing a share of a market valued in the billions. The timeline for this opportunity is long-term, requiring successful completion of multiple clinical phases.
• **Exploration of ANB032 in Lymphoid and Myeloid Immune Cell Dysregulation**: ANB032, an anti-BTLA modulator antibody, targets complex inflammatory diseases involving lymphoid and myeloid immune cell dysregulation. This mechanism could address conditions where other immunomodulators have limited success. The potential market for such a broad-acting immunomodulator is considerable, encompassing various autoimmune and inflammatory disorders. Successful clinical development and identification of specific high-impact indications could lead to a valuable asset. This represents a long-term growth opportunity with significant R&D investment required.
• **Leveraging Strategic Collaborations for Pipeline Acceleration**: AnaptysBio's existing collaboration and license agreements with GlaxoSmithKline, Inc. and Bristol-Myers Squibb are critical growth drivers. These partnerships provide access to significant financial resources, advanced development capabilities, and global commercialization networks. Advancing partnered programs through preclinical and clinical milestones not only generates potential milestone payments but also validates AnaptysBio's platform and reduces the financial burden and risk of independent development. These collaborations offer ongoing opportunities for shared development and potential market access, with timelines dictated by the progress of specific partnered assets.
• **Expansion into New Therapeutic Areas through Antibody Platform**: AnaptysBio's proprietary antibody discovery platform provides a foundation for identifying and developing new therapeutic candidates beyond its current pipeline. The ability to generate novel antibodies targeting various biological pathways allows for potential expansion into additional inflammation, immuno-oncology, or even other therapeutic areas with high unmet medical needs. This ongoing research and development capability ensures a continuous pipeline of potential future drug candidates, offering long-term growth potential as new targets are identified and validated. The timeline for this is continuous, with new programs potentially emerging over several years.

What Opportunities Does ANAB Have?

• Expansion of existing product candidates into additional indications within inflammation and immuno-oncology.
• Potential for new collaboration agreements or out-licensing deals for pipeline assets.
• Advancement of lead candidates (Imsidolimab, Rosnilimab, ANB032) through later stages of clinical development.
• Growth in the global markets for inflammatory and immuno-oncology therapeutics.

What Threats Does ANAB Face?

• Clinical trial failures or unexpected safety concerns for pipeline candidates.
• Intense competition from other biotechnology and pharmaceutical companies developing similar therapies.
• Regulatory hurdles and potential delays in obtaining marketing approvals.
• Patent expirations or challenges to intellectual property.

What Are ANAB's Competitive Advantages?

• **Proprietary Antibody Platform**: Development of differentiated antibody candidates through its specialized discovery platform, leading to unique therapeutic molecules.
• **Novel Mechanisms of Action**: Focus on distinct biological pathways, such as IL-36R inhibition, PD-1 agonism, and BTLA modulation, which may offer advantages over existing treatments.
• **Clinical-Stage Pipeline**: Advanced product candidates like Imsidolimab, Rosnilimab, and ANB032, representing significant R&D investment and potential first-in-class or best-in-class therapies.
• **Strategic Collaborations**: Partnerships with established pharmaceutical companies (GSK, BMS) provide external validation, shared development costs, and potential access to commercialization infrastructure.
• **Intellectual Property**: Patent protection around its antibody candidates and discovery technologies, creating barriers to entry for competitors.

What Does ANAB Do?

AnaptysBio, Inc., incorporated in 2005 and headquartered in San Diego, California, is a clinical-stage biotechnology company dedicated to the discovery and development of therapeutic product candidates for inflammation and immuno-oncology indications. The company, which changed its name from Anaptys Biosciences, Inc. in July 2006, has evolved to focus on its proprietary antibody platform to create novel treatments. Its core business revolves around advancing a pipeline of differentiated antibody programs, either independently or through strategic collaborations with larger pharmaceutical entities. Key product candidates in its pipeline include Imsidolimab, an antibody designed to inhibit the interleukin-36 receptor (IL-36R). This candidate is being developed for the treatment of various dermatological inflammatory diseases, representing a significant area of unmet medical need. Another crucial program is Rosnilimab, an anti-PD-1 agonist antibody. This program aims to augment PD-1 signaling to suppress T-cell driven human inflammatory diseases, offering a distinct approach to modulating immune responses. Furthermore, ANB032, an anti-BTLA modulator antibody, is being developed for its applicability to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation, targeting complex immune pathways. Beyond its wholly-owned pipeline, AnaptysBio actively engages in developing various antibody programs that are advanced to preclinical and clinical milestones under its collaboration agreements. The company has established significant partnerships, including a collaboration and license agreement with GlaxoSmithKline, Inc. (GSK) and Bristol-Myers Squibb (BMS), two global pharmaceutical leaders. These collaborations provide not only potential funding and resources but also validation for AnaptysBio's technological capabilities. Additionally, the company holds license agreements with United Kingdom Research and Innovation and Millipore Corporation, further broadening its intellectual property and research capabilities. AnaptysBio's business model is centered on the rigorous scientific development and clinical testing of its antibody candidates, aiming to bring novel therapies to market for patients suffering from inflammatory and immuno-oncology conditions. With 136 employees, the company maintains a focused approach on its specialized area of biotechnology.

What Products and Services Does ANAB Offer?

• Develops therapeutic product candidates for inflammation and immuno-oncology.
• Focuses on antibody-based therapies, including Imsidolimab, Rosnilimab, and ANB032.
• Imsidolimab inhibits the interleukin-36 receptor (IL-36R) for dermatological inflammatory diseases.
• Rosnilimab is an anti-PD-1 agonist antibody designed to suppress T-cell driven inflammatory diseases.
• ANB032 is an anti-BTLA modulator antibody for inflammatory diseases linked to immune cell dysregulation.
• Engages in collaborations with major pharmaceutical companies like GlaxoSmithKline and Bristol-Myers Squibb.
• Advances antibody programs through preclinical and clinical milestones.
• Operates as a clinical-stage biotechnology company, meaning its products are in development and not yet commercialized.

How Does ANAB Make Money?

• **Research and Development**: Primarily invests in the discovery, development, and clinical testing of proprietary antibody therapeutic candidates.
• **Collaboration and Licensing**: Generates revenue through upfront payments, milestone payments, and potential royalties from licensing agreements with larger pharmaceutical companies for its antibody programs.
• **Pipeline Advancement**: Focuses on progressing its clinical-stage assets (Imsidolimab, Rosnilimab, ANB032) through various phases of clinical trials to demonstrate efficacy and safety.
• **Intellectual Property**: Relies on patents and proprietary technology related to its antibody platform and specific drug candidates to protect its innovations and create value.

What Industry Does ANAB Operate In?

AnaptysBio, Inc. operates within the highly dynamic and research-intensive biotechnology industry, specifically focusing on the therapeutic areas of inflammation and immuno-oncology. This sector is characterized by substantial R&D investments, long development timelines, and high regulatory hurdles. The global market for inflammatory diseases is projected to continue growing, driven by an aging population and increasing prevalence of autoimmune conditions, while the immuno-oncology market is a rapidly expanding segment with significant unmet needs. AnaptysBio's position as a clinical-stage company means its valuation is heavily tied to the success of its drug candidates in clinical trials and subsequent regulatory approvals. The competitive landscape is intense, featuring both large pharmaceutical companies with vast resources and numerous smaller biotech firms vying for breakthroughs. Success often hinges on developing novel mechanisms of action, demonstrating superior efficacy and safety profiles, and securing strategic partnerships for development and commercialization. AnaptysBio's collaborations with GlaxoSmithKline and Bristol-Myers Squibb are crucial for navigating this competitive and capital-intensive environment.

Who Are ANAB's Key Customers?

• **Future Patients**: Individuals suffering from dermatological inflammatory diseases, T-cell driven inflammatory diseases, and other conditions associated with lymphoid and myeloid immune cell dysregulation, who would ultimately benefit from approved therapies.
• **Pharmaceutical Partners**: Large pharmaceutical companies (e.g., GlaxoSmithKline, Bristol-Myers Squibb) that collaborate on development and potentially commercialization, serving as direct partners in bringing therapies to market.
• **Healthcare Providers**: Physicians and specialists who would prescribe AnaptysBio's therapies upon regulatory approval.
• **Payers**: Health insurance companies and government healthcare programs that would cover the cost of approved treatments.

Net buyingInsider Activity

Over the past six months, AnaptysBio, Inc. insiders filed 28 SEC Form 4 transactions — 13 sales and 15 purchases. On net that is roughly 37K shares acquired (about $871K) — insiders putting money in tends to read as conviction.

FY2026 estForward Outlook

Wall Street analysts project AnaptysBio, Inc. revenue of about $110.0M for fiscal 2026, with EPS near $-1.52. The estimate reflects 5 contributing analysts.

F-Score 5/9Financial Health

AnaptysBio, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.94 places it in the safe zone, indicating low near-term bankruptcy risk.

P/E 9.6Key Financial Metrics

Return on assets is 6.8%, showing how much profit it generates from its asset base. ANAB trades at a trailing price-to-earnings ratio of 9.55, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.58 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

AnaptysBio, Inc. (ANAB) Valuation Context

Valued at $2.75B, ANAB is classified as a mid-cap stock. Relative to its peer group, ANAB's quantitative score of 40/100 is below the peer average of 75/100.

ANAB Revenue & Earnings Trend

In Q1 2026, ANAB generated $25.6M in top-line revenue, marking a sequential decrease of 76.4%. The company recorded a net loss of $52.9M, with diluted EPS of $-1.84. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, ANAB averaged $-0.27 in diluted EPS.

Company Profile

AnaptysBio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Daniel R. Faga. ANAB has traded publicly since 2017.

ANAB Financials

ANAB Latest News

ANAB Analyst Consensus

ANAB MoonshotScore

ANAB Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources